Acumen Pharmaceuticals (ABOS) News
NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.1865-0.0068 (-3.52%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABOS news summary
We found 13 recent headlines mentioning Acumen Pharmaceuticals (ABOS): 0 in the past week and 10 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, ABOS is down 3.52% at $0.1865. The most recent story, "Acumen Pharmaceuticals, Inc. Announces 90% Workforce Reduction and Terminates Loan Agreement with $23.3 million Payoff", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Acumen Pharmaceuticals headlines
- Acumen Pharmaceuticals, Inc. Announces 90% Workforce Reduction and Terminates Loan Agreement with $23.3 million PayoffAcumen Pharmaceuticals, Inc. announced that its board of directors approved a restructuring plan on November 1, 2026, to implement cash conservation measures. This plan includes a workforce reduction…Nasdaq
- Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsKey PointsPhase II ALTITUDE-AD trial top-line results are expected in November 2026.Nasdaq
- Acumen Shares Drop 89% After Sabirnetug Fails Phase 2 Alzheimer's Trial(RTTNews) - Acumen Pharmaceuticals, Inc. (ABOS) announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) in patients with early Alzheimer's disease failed to meet its primary…NasdaqABOS, BRK.A
- Acumen Halts Sabirnetug Development After Phase 2 Trial Miss(RTTNews) - Acumen Pharmaceuticals (ABOS) announced that its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer's disease did not meet its primary endpoint of slowing cognitive and…NasdaqABOS, HEI.A
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale…GlobeNewswire
- Acumen Q3 Loss Narrows; Alzheimer's Trial Results Due November 2026(RTTNews) - Acumen Pharmaceuticals, Inc. (ABOS) reported on Monday a narrower third-quarter net loss and said it expects Phase 2 ALTITUDE-AD topline results in November 2026.NasdaqABOS, SUN
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout(RTTNews) - Shares of several biotech companies moved sharply higher following corporate and clinical developments. Surgery Partners surged on reports of a late-stage buyout talks with Bon Secours…NasdaqABOS, ORKA, SGRY, XNCR
- Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqABOS, HEI.A
- Acumen Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Targets November 2026 for ALTITUDE-AD Topline ResultsAcumen Pharmaceuticals, Inc. reported its financial results for the third quarter of 2026 and provided updates on its clinical pipeline. The Company expects to report topline results for ALTITUDE-AD,…Nasdaq
- Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business HighlightsNEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…GlobeNewswire
- Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble…GlobeNewswire
- Tuesday Sector Leaders: Biotechnology, DrugsIn trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.2%. Leading the group were shares of Myriad Genetics, up about 37.5% and shares of Larimar Therapeutics up…NasdaqMYGN, LRMR, ABOS, CPIX
- Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…GlobeNewswire